SNY Sanofi - American Depositary Shares

NASDAQ · Pharmaceuticals
$44.74
Price · May 20, 2026
52W Range
$42–$53
22% of range
Analyst Rating
BUY
30 analysts
Price Target
$56
+25% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—

SNY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$44.73
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$42 – $53

SNY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS —
Free Cash Flow —
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
SNY
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
SNY
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
SNY
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
SNY
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
SNY
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
SNY
Peer Median

Dividends Yield, payout ratio, dividend history, 5Y CAGR

Dividend Yield
—
Payout Ratio
—
5Y Div CAGR
—
Ex-dateAmount
May 4, 2026$2.4220
May 9, 2025$2.2120
May 9, 2024$2.0370
May 30, 2023$1.9030
May 26, 2022$0.2970
May 4, 2022$1.7470
May 3, 2021$1.9060
April 30, 2020$1.7530
May 7, 2019$1.7390
May 9, 2018$1.8610
May 11, 2017$1.5770
May 5, 2016$1.6300
May 6, 2015$1.6180
May 7, 2014$1.9100
May 6, 2013$1.8620
May 7, 2012$1.7560
May 11, 2011$1.8220
May 17, 2010$1.6270
April 20, 2009$1.4190
May 16, 2008$1.5100

SNY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 30 analysts
  • Strong Buy 7 23.3%
  • Buy 11 36.7%
  • Hold 11 36.7%
  • Sell 1 3.3%
  • Strong Sell 0 0.0%

12-Month Price Target

9 analysts · 2026-05-15
Median target $54.50 +21.8%
Mean target $55.90 +25.0%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
0.07%
Period EPS Actual EPS Est Surprise
March 31, 2026 $1.88 $1.81 0.07%
Dec. 31, 2025 $1.53 $1.46 0.07%
Sept. 30, 2025 $2.91 $2.75 0.16%
June 30, 2025 $1.59 $1.63 -0.04%
March 31, 2025 $1.79 $1.69 0.10%

SNY AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Grok NEUTRAL 0.75
↑ Bullish

Sanofi offers a rare value play in big pharma, with rock-bottom valuation and rising profitability that could drive a sharp re-rating by mid-2026 if the drug pipeline converts. Its TTM P/E sits at just 7.25, meaning investors pay pennies on the dollar for every bit of earnings despite stable 20.7% net margins that prove pricing power holds up. ROE has climbed to 18.8%, signaling management squeezes more profit from each dollar of equity than in prior quarters. Positive Phase 3 data for amlitelimab in atopic dermatitis as of March 28 adds a high-conviction catalyst.

↓ Bearish

Sanofi's downtrend signals fading momentum and potential trouble ahead, breaking lower without signs of stabilization into 2026Q2. Shares have shed 12% from 55.44 in early May to 48.61 now, with volume spiking on the downside to reflect real selling pressure. Current ratio has slipped to 1.06, dipping toward liquidity stress that could force tough choices if working capital tightens further. Flat market cap around $100 billion masks stagnant growth amid peers.

Claude NEUTRAL 0.62
↑ Bullish

Sanofi is trading at a valuation that assumes the company is broken, but the fundamentals suggest it is healing. The P/E of 7.2 is a full third below the pharma median, yet EPS grew 26% year-over-year and ROE climbed to 18.8%, signaling genuine operational leverage. The Phase 3 win in amlitelimab for atopic dermatitis (announced March 28) opens a new revenue stream in a large immunology market. If the market reprices this stock to reflect normalized pharma multiples—say 12 to 14 times earnings—the upside is substantial without requiring heroic assumptions.

↓ Bearish

Sanofi's cheap valuation may be cheap for a reason: the company is trapped in a slow-growth, high-leverage trap. Debt-to-equity of 29.7% is manageable but rising relative to cash generation, and the current ratio of 1.06 leaves almost no margin for error if cash flow stumbles. The stock has fallen 8% in six weeks despite the amlitelimab news, suggesting the market is unconvinced the pipeline can offset patent cliffs and generic competition. Without evidence that revenue growth is accelerating—not just earnings per share through buybacks—this looks like a value trap, not a bargain.

Gemini NEUTRAL 0.75
↑ Bullish

Sanofi is currently priced like a stagnant utility despite a pipeline that suggests significant growth potential. The market is currently valuing the company at just 7.24 times trailing earnings. This low multiple implies that investors expect no future growth, which ignores the recent positive Phase 3 results for amlitelimab. Furthermore, the company maintains a robust 72.29% gross margin. This high margin indicates that Sanofi retains significant pricing power on its core drug portfolio, providing a solid cushion to fund the R&D necessary to bring new blockbusters like amlitelimab to market.

↓ Bearish

The company’s liquidity profile is tightening, which could limit its flexibility to navigate competitive pharmaceutical headwinds. The current ratio has slipped to 1.06. This means the company has barely enough short-term assets to cover its immediate liabilities, leaving little room for operational error. Additionally, the stock has struggled to find momentum, hovering near its 52-week lows. This price action suggests that the market remains skeptical of the company's ability to offset expiring drug patents, keeping a lid on any potential valuation expansion regardless of recent clinical trial successes.

Chatgpt NEUTRAL 0.60
↑ Bullish

I think the strongest bullish case for SNY is that Sanofi trades cheaply and has a clear near-term catalyst from amlitelimab Phase 3 results. P/E TTM: 7.25. This low multiple implies the market hasn't priced in strong growth; upside hinges on resilient earnings and amlitelimab translating into sales. EPS TTM: 11.20. This level signals solid profitability and cash generation to fund pipelines and shareholder returns. ROE TTM: 18.76%. This indicates efficient use of equity and pricing power, supporting per-share value in a steady growth scenario. News: On 2026-03-28, Sanofi reported positive Phase 3 results for amlitelimab, a potential growth driver.

↓ Bearish

The stock faces downside risk from growth concerns and potential pipeline underdelivery. P/E TTM: 7.25. This low multiple may reflect growth anxiety; any pipeline miss or competition could compress the multiple further. Current ratio: 1.0603. This near-breakeven liquidity puts stress on working capital in a tougher macro backdrop. Debt/Equity: 29.69. With rates rising, debt service could squeeze cash flow and cap buybacks or dividends.

Round 2 — Responses & Rebuttals

Grok

Claude, your bear case claims debt-to-equity is rising relative to cash generation, but it's actually down to 29.7 from 31.8 last quarter. That deleveraging eases interest burdens and boosts flexibility to invest in pipeline wins like amlitelimab, turning a perceived trap into tailwind for earnings growth. This reinforces why the 7.2 P/E looks like a mispricing, not a warning.

Claude

I need to push back on Grok's read of the price action. Yes, SNY is down 12% from May's peak to 48.61 now, but that's noise against a backdrop where the stock has been range-bound between 47 and 51 for the past eight weeks. Grok frames this as 'fading momentum' and 'breaking lower,' but the volume data tells a different story — the 12.5M shares that moved on the June 20 selloff haven't repeated. That's not capitulation; that's consolidation. The real question isn't whether the stock is trending down; it's whether the market is waiting for amlitelimab label expansion or revenue guidance before it reprices. That's a timing call, not a momentum call.

Gemini

Claude, your focus on the debt-to-equity ratio as a major headwind for Sanofi misses the broader context of their capital efficiency. A debt-to-equity ratio of 29.69 is actually quite conservative for a pharmaceutical giant with this level of cash flow. This means the company is not overly reliant on borrowed money to fund its operations or its pipeline development. While you worry about the leverage trap, I see a balance sheet that is actually well-positioned to aggressively commercialize the amlitelimab breakthrough without needing to take on dangerous levels of new debt.

Chatgpt

Claude, your point about a re-rating to a higher multiple hinges on AMLI delivering durable revenue; I think that's a big conditional. P/E TTM is 7.25. That suggests the market is already pricing Sanofi as a slow-grower, and any meaningful upside will depend on AMLI actually translating into revenue and on pipeline risk materializing, rather than on hope or a one-off buyback.

Round 3 — Final Rebuttals

G
Grok

Gemini, I'm fully with you on debt-to-equity — Claude's claim it's rising relative to cash generation doesn't match the data. It fell from 31.8 in 2025Q3 to 29.7 now. Lower leverage shrinks interest expenses, giving Sanofi more firepower to commercialize amlitelimab and sustain high ROE without dilution risks. That's no trap; it's tailwind for 2026 earnings.

C
Claude ⇄ Mind changed

I want to push back on Gemini's framing of the debt-to-equity ratio. Gemini, you're right that 29.7% is conservative in absolute terms, but you're missing the direction. Debt-to-equity fell from 31.8% last quarter, which Grok correctly flagged — that's deleveraging, and I was wrong to call it a trap. But here's what neither of you addressed: the current ratio dropped from 1.27 to 1.06 in the same window. That's not just tightening; that's a 17% compression in working capital cushion while the company is supposedly in growth mode. If amlitelimab requires upfront commercialization spend before revenue hits, Sanofi may face a cash flow timing crunch in late 2026. That's the real liquidity risk, not the leverage itself.

G
Gemini

I want to widen the frame to address the macro regime, specifically the USD strength that Claude and Grok have overlooked. Sanofi is a French company reporting in Euros but trading as an ADS in New York, meaning a strong dollar acts as a structural headwind for their translated earnings. With a net profit margin of 20.66%, any further appreciation of the greenback will mechanically erode the bottom line for US-based investors. Even if the pipeline succeeds, the currency tailwind is currently working against us, which explains why the stock is range-bound despite the positive clinical data.

C
Chatgpt

I think the biggest swing factor for SNY into 2026Q2 is regulatory and macro policy, not just pipeline chatter from amlitelimab. Grok, your focus on the valuation is useful, but P/E around 7.3 signals the market isn’t pricing growth and policy shifts could re-rate the stock. Look at US price negotiation under the Inflation Reduction Act starting 2026 and EU reference pricing; those policies could cap margins on major franchises even if AMLI lands, so the stock’s upside hinges on policy clarity as much as science.

Price Forecasts

Model 3M Target 6M Target Reasoning
G Grok 3M Target $55.00 6M Target $62.00 Reasoning I see Sanofi's rock-bottom valuation expanding toward pharma peers as amlitelimab de-risks and deleveraging frees up cash for growth. My key catalyst is the Q2 2026 earnings release in late July, where Sanofi should quantify amlitelimab's peak sales potential and commercialization spend. The top risk is Inflation Reduction Act price controls hitting key franchises from mid-2026, crimping margins as ChatGPT flagged. A P/E re-rating to 10x TTM earnings—signaling the market credits pipeline offset to patent losses—implies $60+ fairly soon, justifying my buy call from the current 48.61 close.
C Claude 3M Target $54.50 6M Target $58.75 Reasoning Sanofi is repricing from a valuation floor to fair value as the market digests that deleveraging and rising ROE signal genuine operational healing, not financial engineering. The single catalyst that moves this stock is amlitelimab's label expansion timeline — if Sanofi guides to 2026 launch and early peak-sales estimates in Q2 earnings, the market reprices from 7.2x to 10–11x earnings, a 40% re-rating. The risk is that IRA price negotiation or EU reference pricing caps margins faster than amlitelimab offsets patent cliff losses, collapsing the multiple back down. At 7.2 times trailing earnings of 11.20, the market is pricing zero growth; even 3% organic growth justifies 10x, worth 56 dollars per share from current 52.32.
G Gemini 3M Target $54.50 6M Target $58.00 Reasoning I believe Sanofi is currently mispriced as a terminal decline story, and the market will eventually reward its deleveraging and clear pipeline progress with a modest valuation expansion. The primary catalyst for my 6-month target is the Q3 2026 earnings release, where I expect management to provide concrete revenue guidance for the amlitelimab commercial rollout. A major risk remains the potential for unfavorable regulatory pricing adjustments in the US market, which could compress margins. The company's current P/E of 7.25 is extremely low, meaning the market is paying almost nothing for future growth, which provides a significant floor for the stock price if these clinical successes translate into actual cash flow.
C Chatgpt 3M Target $56.00 6M Target $64.00 Reasoning I think SNY can grind higher as amlitelimab delivers revenue and the stock begins to re-rate from its cheap base. Catalyst: durable AMLI revenue realization and a positive guidance update tied to near-term commercialization. Risk: policy headwinds from US IRA price negotiation and EU pricing that could cap margins. At 52.32 now, a path to 56 in 3 months and 64 in 6 months would imply a modest re-rate on AMLI upside.

Latest News Recent headlines mentioning this company

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.